Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (61-70 of 275) with videos related to

Pageof 28
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2016
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?Alexander Drilon, Federico Cappuzzo, Sai-Hong Ignatius Ou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2022
KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: "Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously"Stefano Scalera, Marco Mazzotta, Federico Cappuzzo, et al.
Cancer Treatment Reviews|November 29, 2011
EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospectsJean-Charles Soria, Tony S Mok, Federico Cappuzzo, et al.
Expert Opinion on Emerging Drugs|February 1, 2012
Emerging drugs for small cell lung cancer--an updateGiulio Metro, Simona Duranti, Matthias Joachim Fischer, et al.
Biologics : Targets & Therapy|April 22, 2025
Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative ReviewAndrea Torchia, Giuliana Ciappina, Maristella Giammaruco, et al.
Drugs|May 1, 2016
Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?Raffaele Califano, Ourania Romanidou, Giannis Mountzios, et al.
Oncology (Williston Park, N.Y.)|September 1, 2005
Perspectives on salvage therapy for non-small-cell lung cancerFederico Cappuzzo, Giovanna Finocchiaro, Rocco Trisolini, et al.
JTO Clinical and Research Reports|December 9, 2025
DESTINY of Immunotherapy in Patients With <i>HER2</i> Mutant Lung Cancer: Case ReportLorenza Landi, Francesca Fusco, Enrico Melis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 11, 2009
MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinibFederico Cappuzzo, Marileila Varella-Garcia, Elisa Rossi, et al.
Frontiers in Oncology|March 2, 2026
Comparative efficacy of trastuzumab deruxtecan versus guideline-recommended treatments for 2L+ unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer: a systematic review and indirect treatment comparisonFederico Cappuzzo, Lirong Zhang, Kyle Dunton, et al.
Pageof 28

Showing results (61-70 of 275) with videos related to

Sort By:
Pageof 28
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2016
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?Alexander Drilon, Federico Cappuzzo, Sai-Hong Ignatius Ou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2022
KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: "Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously"Stefano Scalera, Marco Mazzotta, Federico Cappuzzo, et al.
Cancer Treatment Reviews|November 29, 2011
EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospectsJean-Charles Soria, Tony S Mok, Federico Cappuzzo, et al.
Expert Opinion on Emerging Drugs|February 1, 2012
Emerging drugs for small cell lung cancer--an updateGiulio Metro, Simona Duranti, Matthias Joachim Fischer, et al.
Biologics : Targets & Therapy|April 22, 2025
Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative ReviewAndrea Torchia, Giuliana Ciappina, Maristella Giammaruco, et al.
Drugs|May 1, 2016
Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?Raffaele Califano, Ourania Romanidou, Giannis Mountzios, et al.
Oncology (Williston Park, N.Y.)|September 1, 2005
Perspectives on salvage therapy for non-small-cell lung cancerFederico Cappuzzo, Giovanna Finocchiaro, Rocco Trisolini, et al.
JTO Clinical and Research Reports|December 9, 2025
DESTINY of Immunotherapy in Patients With <i>HER2</i> Mutant Lung Cancer: Case ReportLorenza Landi, Francesca Fusco, Enrico Melis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 11, 2009
MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinibFederico Cappuzzo, Marileila Varella-Garcia, Elisa Rossi, et al.
Frontiers in Oncology|March 2, 2026
Comparative efficacy of trastuzumab deruxtecan versus guideline-recommended treatments for 2L+ unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer: a systematic review and indirect treatment comparisonFederico Cappuzzo, Lirong Zhang, Kyle Dunton, et al.
Pageof 28